Robert J. Schott's most recent trade in Sangamo Therapeutics Inc was a trade of 110,700 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 25, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Robert J. Schott | SVP, Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 110,700 | 110,700 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Robert J. Schott | SVP, Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 41,000 | 75,537 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Robert J. Schott | SVP, Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.76 per share. | 12 Feb 2022 | 5,463 | 34,537 (0%) | 0% | 5.8 | 31,467 | Common Stock |
| Sangamo Therapeutics Inc | Robert J. Schott | SVP, Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Robert J. Schott | SVP, Head of Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 40,000 | 40,000 (0%) | 0% | 0 | Common Stock |